Win the Patent War Before the Drug Goes Generic: How Paragraph IV Challenges and Pay-for-Delay Settlements Decide Who Gets Paid — and Who Gets Blocked
In the high-stakes world of pharmaceuticals, the battle over patent rights isn’t just about innovation—it’s about who profits, who gets blocked, and ultimately, who has access to life-saving medicines. As the industry faces mounting pressure to balance…
